#Germany #neonatal care #Dräger #BiliPredics #Lübeck

Dräger Introduces BiliPredics for Enhanced Neonatal Care

In a significant advancement in neonatal care, Dräger has recently unveiled BiliPredics, a cutting-edge predictive software solution designed to improve the management of neonatal jaundice. Developed in partnership with NeoPredics, BiliPredics leverages an advanced algorithm to forecast bilirubin levels up to 60 hours in advance, allowing healthcare professionals to make timely and informed decisions. This innovative tool represents a major step towards enhancing neonatal health outcomes by enabling early intervention and more effective care strategies.

Understanding Neonatal Jaundice

Neonatal jaundice is a common condition that affects many newborns, particularly premature infants. It occurs when there is a build-up of bilirubin, a yellow pigment produced during the breakdown of red blood cells. If bilirubin levels become excessively high, it can lead to serious health complications. Therefore, effective monitoring and intervention are crucial in the early stages of a newborn's life.

Key Features of BiliPredics

BiliPredics offers a host of features aimed at improving the management of jaundice:

• - Predictive Analytics: Using over 50,000 bilirubin measurements from nearly 10,000 newborns, BiliPredics allows clinicians to predict bilirubin levels and trends with remarkable accuracy. This data-driven approach supports better clinical decision-making.
• - Comprehensive Dashboard: The BiliPredics interface presents healthcare providers with a clear overview of predicted bilirubin progression along with vital additional information. This ensures that clinicians have access to critical data right at their fingertips.
• - Integrated Clinical Workflow: BiliPredics aligns with established guidelines such as the 2022 AAP Hyperbilirubinemia Guideline, and can seamlessly integrate with electronic medical records (EMR). This integration facilitates real-time monitoring and enhances discharge planning by reducing unnecessary treatments and hospital stays.

Importance of Early Intervention

The proactive nature of BiliPredics is especially crucial given that approximately 50% of all newborns and up to 80% of preterm infants experience neonatal jaundice. By forecasting bilirubin trends, BiliPredics can assist healthcare providers in initiating preventive measures, potentially preventing complications and ensuring better outcomes for infants and their families.

Dr. Harald Kneuer, Director of Neonatal Care at Dräger, emphasized the importance of this innovation: "Through our collaboration with NeoPredics, we aim to strengthen our offerings in jaundice management. Combining Dräger's expertise with NeoPredics' advanced analytics empowers healthcare professionals with essential tools for improving patient outcomes."

A Strategic Partnership

This partnership between Dräger and NeoPredics marks a pivotal moment in neonatal care. Thorsten Waloschek, CEO of NeoPredics, shared, "Together, we are bridging innovative technology with clinical expertise to tackle pressing challenges in managing neonatal jaundice."

In addition to BiliPredics, Dräger's portfolio includes tools for both screening and treatment, such as the non-invasive Dräger Jaundice Meter JM-105 and the effective BiliLux™ Phototherapy Light. These products embody a comprehensive approach to jaundice management, following the latest guidelines in care.

About Dräger and NeoPredics

Founded in 1889, Dräger is a global leader in medical technology dedicated to protecting and saving lives. With a presence in over 190 countries, Dräger generated sales of approximately EUR 3.4 billion in 2023. The partnership with NeoPredics enhances its commitment to innovation in the healthcare sector. NeoPredics specializes in predictive analytics focused on maternal and neonatal health, contributing to advancements that improve outcomes for mothers and children.

For further information on Dräger's neonatal care solutions, visit Dräger's website. To learn more about NeoPredics, check out NeoPredics' website.